Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorGUILLOT, Jordan
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMAUMUS-ROBERT, Sandy
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMARCERON, Alexandre
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorNOIZE, Pernelle
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
ORCID: 0000-0002-2568-1928
IDREF: 181595710
dc.date.accessioned2021-03-15T15:28:24Z
dc.date.available2021-03-15T15:28:24Z
dc.date.issued2020-11-20
dc.identifier.issn2077-0383 (Print) 2077-0383 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26664
dc.description.abstractEnWe aimed to describe the burden represented by potentially inappropriate medications (PIMs) in chronic polypharmacy in France. We conducted a nationwide cross-sectional study using data from the French National Insurance databases. The study period was from 1 January 2016 to 31 December 2016. Chronic drug use was defined as uninterrupted daily use lasting ?6 months. Chronic polypharmacy was defined as the chronic use of ?5 medications, and chronic hyperpolypharmacy as the chronic use of ?10 medications. For individuals aged ?65 (older adults), PIMs were defined according to the Beers and Laroche lists, and for individuals aged 45-64 years (middle-aged) PIMs were defined according to the PROMPT (Prescribing Optimally in Middle-aged People's Treatments) list. Among individuals with chronic polypharmacy, 4009 (46.2%) middle-aged and 18,036 (64.8%) older adults had at least one chronic PIM. Among individuals with chronic hyperpolypharmacy, these figures were, respectively, 570 (75.0%) and 2544 (88.7%). The most frequent chronic PIM were proton pump inhibitors (43.4% of older adults with chronic polypharmacy), short-acting benzodiazepines (older adults: 13.7%; middle-aged: 16.1%), hypnotics (6.1%; 7.4%), and long-acting sulfonylureas (3.9%; 12.3%). The burden of chronic PIM appeared to be very high in our study, concerning almost half of middle-aged adults and two-thirds of older adults with chronic polypharmacy. Deprescribing interventions in polypharmacy should primarily target proton pump inhibitors and hypnotics.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enThe Burden of Potentially Inappropriate Medications in Chronic Polypharmacy
dc.title.alternativeJ Clin Meden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/jcm9113728en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33233595en_US
bordeaux.journalJournal of Clinical Medicineen_US
bordeaux.page3728en_US
bordeaux.volume9en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03169788
hal.version1
hal.date.transferred2021-03-15T15:28:28Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Clinical%20Medicine&rft.date=2020-11-20&rft.volume=9&rft.issue=11&rft.spage=3728&rft.epage=3728&rft.eissn=2077-0383%20(Print)%202077-0383%20(Linking)&rft.issn=2077-0383%20(Print)%202077-0383%20(Linking)&rft.au=GUILLOT,%20Jordan&MAUMUS-ROBERT,%20Sandy&MARCERON,%20Alexandre&NOIZE,%20Pernelle&PARIENTE,%20Antoine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée